valcyte主治什么？

What does it treat? Valcyte is an oral anti-cytomegalovirus infection drug that combines the advantages of oral administration and intravenous injection. It can effectively prevent and treat cytomegalovirus infection through correct oral administration every day, significantly improving the patient's quality of life and long-term survival rate.

Valcyte is indicated for the treatment of: Cytomegalovirus (CMV) prophylaxis in high-risk adult kidney, heart, and pancreas transplant patients (donor CMV seropositive/recipient CMV seronegative). Prevention of cytomegalovirus (CMV) in high-risk children with kidney transplantation (4 months to 16 years old) and heart transplantation (1 month to 16 years old). Cytomegalovirus Retinitis, Treatment (AIDS-Related): Treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS).

Adult patients should use valcyte instead of valcyte oral solution. Oral solutions and tablets should be taken with food. Valcyte tablets should not be broken or crushed. Before dispensing the medication to a patient, the pharmacist must prepare an oral solution (50 mg/ml) with valcyte.

Next, let’s look at the recommended dosage of valcyte for adults with normal renal function:

Treatment of induction of cytomegalovirus retinitis: The recommended dose is 900 mg (two 450 mg tablets) twice daily for 21 days.

Maintenance: After induction therapy, or in adult patients with inactive cytomegalovirus retinitis, the recommended dose is 900 mg orally once daily.

  Cytomegalovirus prophylaxis: For adult patients who have received a heart or kidney-pancreas transplant, the recommended dose is 900 mg orally once daily starting within 10 days of transplantation and continuing until 100 days after transplantation.

  For adult patients who have received a kidney transplant, the recommended dose is 900 mg taken orally once daily starting within 10 days after transplantation and until 200 days after transplantation.